Financial Performance - Net income for Q1 fiscal 2025 was $1.5 million, or $0.24 net income per share basic, compared to a net loss of $8.1 million in Q1 fiscal 2024[16]. - Total net revenue for Q1 fiscal 2025 was $16.6 million, a decrease from $17.8 million in the prior year period, primarily due to changes in payor coverage[12]. - Net revenue for the three months ended September 30, 2024, was $16,574,000, a decrease of 7% from $17,817,000 for the same period in 2023[23]. - The company reported a net income of $1,474,000 for the three months ended September 30, 2024, compared to a net loss of $8,120,000 for the same period in 2023[23]. - Aytu BioPharma reported a net loss of $4,617,000 for the three months ended June 30, 2024, compared to a net loss of $2,887,000 for the previous quarter[27]. - Aytu BioPharma's total net loss for the twelve months ended June 30, 2024, was $15,844,000[27]. Revenue and Market Performance - ADHD Portfolio net revenue increased 1% to $15.3 million in Q1 fiscal 2025, while Pediatric Portfolio net revenue increased 54% sequentially to $1.3 million[2]. - Approximately 99,000 ADHD prescriptions were written in Q1 fiscal 2025, compared to 90,000 in Q1 2023, indicating a recovery in the ADHD market[3]. Expenses and Cost Management - Adjusted EBITDA for Q1 fiscal 2025 was $1.9 million, down from $2.4 million in Q1 fiscal 2024[17]. - Operating expenses, excluding amortization and restructuring costs, were $11.2 million in Q1 fiscal 2025, down from $13.0 million in the prior year period[14]. - Total operating expenses decreased to $12,915,000 from $13,905,000, primarily due to reductions in selling and marketing expenses[23]. - The company implemented an organizational optimization plan expected to reduce operating expenses by at least $2.0 million annually[4]. - The company is focusing on restructuring costs, which amounted to $784,000 for the three months ended September 30, 2024, as part of its strategic initiatives[23]. Cash and Assets - Cash and cash equivalents were $20.1 million at September 30, 2024, compared to $20.0 million at June 30, 2024[17]. - Cash and cash equivalents as of September 30, 2024, were $20,108,000, slightly up from $20,006,000 as of June 30, 2024[24]. - Total assets decreased to $115,831,000 from $118,095,000, indicating a reduction in the company's asset base[24]. - Current liabilities increased to $61,252,000 from $62,228,000, reflecting changes in accounts payable and accrued liabilities[24]. Profitability Metrics - Gross profit percentage was 72% in Q1 fiscal 2025, down from 73% in Q1 fiscal 2024[2]. - Gross profit for the same period was $11,985,000, down from $13,038,000, reflecting a gross margin decrease[23]. - Adjusted EBITDA for the three months ended September 30, 2024, was $1,931,000, down from $2,415,000 in the same period last year[25]. Other Financial Metrics - Interest expense for the quarter was $1,253,000, slightly down from $1,266,000 in the previous quarter[27]. - The company incurred restructuring costs of $1,912,000 during the quarter, indicating ongoing operational adjustments[27]. - Pipeline research and development costs amounted to $599,000, reflecting continued investment in new product development[27]. - Total income tax expense for the quarter was $695,000, up from $245,000 in the previous quarter[27]. - Stock-based compensation expense was $243,000, a decrease from $699,000 in the previous quarter[27]. - The company reported a gain of $1,463,000 from derivative warrant liabilities, a significant improvement from a loss of $1,017,000 in the previous quarter[27]. Strategic Initiatives - The company successfully completed the wind down and divestiture of its Consumer Health business, marking the end of its restructuring efforts[9].

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q4 2024 Results Conference Call September 26, 2024 4:30 PM ET Company Participants Robert Blum - IR, Lytham Partners Josh Disbrow - Chief Executive Officer Mark Oki - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Operator Greetings, welcome to the Aytu BioPharma's Fiscal 2024 Q4 Earnings Call. At this time, all participants have been placed on a listen-only mode. [Operator Instructions] Please note this conference is being recorded. I will n ...

Exhibit 99.1 Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results Full year fiscal 2024 consolidated net revenue of $81.0 million; Rx Segment net revenue of $65.2 million Full year fiscal 2024 ADHD Portfolio net revenue up 23% compared to fiscal 2023 Full year fiscal 2024 adjusted EBITDA1 improved to $9.2 million, up by $5.7 million compared to fiscal 2023 $20.0 million cash balance at June 30, 2024 Company expects Rx Segment net revenue and adjusted EBITDA growt ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-38247 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Common Stock, par value $0.0001 per share AYTU The Nasdaq Capital Market Securities registered pursu ...

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q3 2024 Earnings Call Transcript May 15, 2024 4:30 PM ET Company Participants Roger Weiss - Investor Relations Joshua Disbrow - Chief Executive Officer Mark Oki - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Jennifer Kim - Cantor Fitzgerald Operator Good afternoon, everyone and welcome to the Aytu BioPharma Fiscal 2024 Third Quarter Earnings Call. At this time, all participants have been placed on a listen-only mode. [Operator Instructions] ...

Exhibit 99.1 Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results Q3 2024 ADHD Portfolio net revenue up 49% compared to Q3 2023 Q3 2024 adjusted EBITDA1 improved by $7.0 million compared to Q3 2023 TTM March 2024 operating income of $7.3 million for the Rx Business TTM March 2024 companywide adjusted EBITDA of positive $15.4 million TTM March 2024 adjusted EBITDA of positive $17.1 million for the Rx Business $19.8 million cash balance at March 31, 2024 Company to host conferenc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ___________ Commission File No. 001-38247 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 47-0883144 (State or other j ...

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2024 Earnings Conference Call February 14, 2024 4:30 PM ET Company Participants Roger Weiss - Investor Relations Joshua Disbrow - Chief Executive Officer Mark Oki - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Operator Greetings. Welcome to the Aytu BioPharma Fiscal 2024 Q2 Earnings Call. [Operator Instructions] Please note, this conference is being recorded. I will now turn the conference over to your host, Roger Weiss. You may begin. R ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ___________ Commission File No. 001-38247 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 47-0883144 (State or othe ...

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2024 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Robert Blum - IR Josh Disbrow - CEO Mark Oki - CFO Conference Call Participants Naz Rahman - Maxim Group Robert Blum Good afternoon, everyone, and thank you for joining us for Aytu BioPharma's Fiscal 2024 First Quarter Financial Results Conference Call for the period ended September 30, 2023. Joining us on today's call is Aytu’s CEO, Josh Disbrow, and the company's Chief Financial Officer, M ...